News
Article
Author(s):
In case you missed it, this week we had news about Alphyn Biologics' first patient dosed with zabalafin hydrogel, abrocitinib for Netherton Syndrome, the ICONIC-LEAD phase 3 study, and more.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Novel Injection Technique Prevents Sunken Cheek in Masseter Hypertrophy Treatment
The method was safe and effective with high patient satisfaction rates 4 weeks post-injection.
Shaping the Future of Dermatology With Insights From AAD 2025 and Beyond
Explore key takeaways from AAD 2025, rosacea insights, psoriasis updates, and expert interviews in the latest issue of Dermatology Times.
Study Reports Efficacy of Tofacinitib in Itch, Skin Infiltration Reduction for Prurigo Nodularis
Tofacitinib showed promise for easing itch and skin symptoms in prurigo nodularis, though effects may lessen over time.
Large-Spot, Variable-Pulsed KTP Laser Demonstrates Safety and Efficacy in Port-Wine Birthmarks
Long-pulsed KTP laser showed promise as a safe, effective alternative to PDL for treating port-wine birthmarks over 3 years.
Bridging Medicine and Machine Learning
The guide prepares students to critically engage with AI tools and understand their real-world implications.
Allergic Contact Dermatitis Remains Prevalent, Negatively Impacts Quality of Life
Researchers conducted a comprehensive review of ACD, detailing the condition’s epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic options.
Patients reported the face, neck, and inner arms as the most affected body regions before treatment.
Championing Patient and Consumer Safety in Dermatology
Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.
Alphyn Doses First Patient in Phase 2b Trial for Zabalafin Hydrogel
Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis.
Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy
After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.
Abrocitinib Shows Promise as a Therapy for Netherton Syndrome
A new case report demonstrated the JAK inhibitor’s efficacy at improving disease severity up to 6 months.
Dupilumab Shows No APO Risk During Pregnancy
Compared to untreated patients, dupilumab-treated women showed no increased risk for spontaneous abortion, gestational diabetes, or hypertensive disorders.
Oxymetazoline 1% Cream Reduces Erythema in Patients with Rosacea
The product was safe and effective after 4 weeks of topical use, specifically on patients with darker skin types.
Kesty Redness Scale Enhances Analysis of Facial Erythema, Study Reports
The Kesty Redness Scale offers a validated, easy-to-use tool to reliably assess facial redness in clinical dermatology.
This review of the latest dermatologic studies includes insights into disparities in pediatric atopic dermatitis, nurse-led models for skin cancer detection, and more.
Pediatric AD Disparities in the United States: An Updated Review
Recent literature shows that children from racial minority groups with lower-income families have higher disease prevalence but reduced access to care.
Personalized Approaches to Atopic Dermatitis: Balancing Burden, Treatment, and Patient Preferences
Raj Chovatiya, MD, PhD, MSCI, explores case-based approaches to managing atopic dermatitis, focusing on treatment strategies, challenges, and clinical insights for improving patient outcomes.
Enzymatic Debridement Is More Effective than Autolytic for Severe Wounds
Although both methods were well tolerated, enzymatic debridement worked faster in randomized controlled trials.
Addressing Diagnostic Ambiguity and Expanding Therapeutic Options in CHE
Raj Chovatiya, MD, PhD, MSCI, discusses his approach to diagnosing and treating chronic hand eczema.
JAAD Study Validates Avava’s Precision Laser Innovation
Physicians can customize treatment depth and intensity with Avava’s system, improving results for various skin concerns.
The study revealed high disease burden, poor quality of life, and need for more effective, targeted treatments.
Bridging the Gap Between Translational Research and Clinical Practice
Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease.
A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.
Choosing the Correct Skin Care for Rosacea with skinbetter science and Zoe Diana Draelos, MD
For Rosacea Awareness Month, Zoe Diana Draelos, MD, spoke to Dermatology Times about skinbetter’s Mystro Active Balance Serum and its NRS Seal of Acceptance.
Henry Lim, MD, discusses the ILDS’ renewed WHO relations status and the global crisis of corticosteroid misuse in skin-bleaching products.
Microneedles Offer a New Hope for Nodular Acne Treatment
Microneedles successfully penetrated simulated skin barriers, suggesting their effectiveness in reaching sebaceous glands.
POLL: Which Cosmeceuticals Are Most Popular, According to Social Media?
Google search trends and TikTok view counts were used to analyze the public popularity of cosmeceutical ingredients like retinol, hyaluronic acid, and niacinamide.
How to Best Support Women With Menopausal Acne
Menopausal acne is rising yet underexplored; treatment must address hormonal shifts, skin sensitivity, and patient emotional well-being.
Codex Labs Lotion is First Eczema OTC Topical to Achieve Microbiome-Friendly Certification
The company also announced in a press release that the product received the Seal of Acceptance by the NEA.
Subcutaneous Methotrexate Shows Promise Over Oral Route in Plaque Psoriasis Treatment
Subcutaneous methotrexate may offer improved efficacy and patient adherence in psoriasis treatment, though it comes at a higher cost.
Exploring Off-Label Uses of Topical JAK Inhibitors
While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.
New Qtorin Rapamycin Data Featured at World Congress of Pediatric Dermatology
The presentation, led by Amy Paller, MS, MD, highlighted the upcoming phase 3 SELVA study for microcystic lymphatic malformations.
Acupuncture Reduces Frown Lines in Clinical Trial
Satisfaction levels remained high at 12 weeks post-treatment among those who received acupuncture.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.